drugset / Trial / NCT01862900
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Phase 1
Completed
14 enrolled
Providence Health & Services
MedImmune LLC · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collabRobert W. Franz Cancer Center · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have progressive disease. The investigators hypothesize that SBRT directed at metastatic breast cancer lesions will result in a systemic anti-tumor immune system response. This amplified and directed immune response could result in anti-tumor responses.
Timeline
- Start
- 2012-04-27
- Primary completion
- 2016-05-17
- Completion
- 2018-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI6469 | Monoclonal antibody | 0.4 mg/kg | Intravenous |